The companies will create an assay to test the human liver toxicity of new drugs.

ReNeuron and CellSeed signed a collaboration agreement to develop liver-cell culture systems for drug safety screening in the pharmaceutical industry.

The development work, to be conducted in CellSeed’s laboratories in Tokyo, will establish protocols for developing ReNeuron’s ReNcell™ HEP hepatocyte cell-lines in combination with CellSeed’s UpCell and HydroCell temperature-sensitive polymer products for 3-D functional liver tissue.

3-D liver culture systems represent a way to assay for human liver toxicity of new drugs. The collaboration will enable the joint development of human cell-based drug discovery products for use in the pharmaceutical industry.

Previous articleVistaGen and Sanwa Renew Embryonic Stem Cell Partnership to Treat Diabetes
Next articleAngel to Manufacture Materials for CellCure Phase II Trials